drugset / Trial / NCT01932970
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
Timeline
- Start
- 2013-08-12
- Primary completion
- 2014-01-14
- Completion
- 2017-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etelcalcetide | Other / unclassified | 5 mg | Intravenous |